J&J agrees $25bn Guidant deal

Pharmaceutical giant Johnson & Johnson has agreed to buy medical technology firm Guidant for $25.4bn (Â£13bn). Analysts said that the deal is aimed at offsetting Johnson & Johnson's reliance on a slowing drug business.